Skip to main content
. 2017 Dec 8;18(12):2661. doi: 10.3390/ijms18122661

Figure 3.

Figure 3

A possible mode of action of HET0016 in relation to growth factor pathways. (a) Treatment with vatalanib causes a decrease in expression of vascular endothelial growth factor receptor 2 (VEGFR2), but increases the expression of hypoxia-inducible factor 1 α (HIF-1α) and VEGF, which will cause increased neovascularization and tumor growth; (b) When HET0016 alone is used, VEGF expression is decreased through different signaling pathways, which will cause decreased neovascularization and tumor growth; (c) When HET0016 and vatalanib are used together some of the effects of vatalanib (increased VEGF, increased neovascularization and tumor growth) can be attenuated. Data obtained from Shankar et al. [46].